Short Interest in Elekta AB (OTCMKTS:EKTAY) Expands By 154.7%

Elekta AB (OTCMKTS:EKTAY) saw a large growth in short interest in the month of May. As of May 29th, there was short interest totaling 1,732 shares, a growth of 154.7% from the May 14th total of 680 shares. Based on an average trading volume of 3,159 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.0% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut Elekta from a “hold” rating to a “strong sell” rating in a research note on Tuesday, June 2nd. Two equities research analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Elekta Stock Up 0.9%

EKTAY stock opened at $5.56 on Friday. The firm has a 50-day moving average price of $5.96 and a 200-day moving average price of $6.06. The stock has a market capitalization of $2.05 billion, a P/E ratio of -34.75 and a beta of 1.00. Elekta has a 12 month low of $4.35 and a 12 month high of $6.93. The company has a current ratio of 0.95, a quick ratio of 0.73 and a debt-to-equity ratio of 0.56.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings results on Thursday, May 28th. The company reported $0.06 earnings per share (EPS) for the quarter. Elekta had a negative net margin of 3.32% and a positive return on equity of 10.67%. The firm had revenue of $521.00 million during the quarter. As a group, equities research analysts anticipate that Elekta will post 0.43 EPS for the current fiscal year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.